In another study [179] CD30.CAR‐Ts co‐expressing the cognate receptor for CCL17, CCR4 (CCR4.CD30.CAR‐Ts) with improved tumor homing and anti‐lymphoma activity compared with CD30.CAR‐Ts not expressing CCR4 were used to treat 8 R/R cHL patients, with 6 (75%) achieving a CR and 2 (25%) a PR. Here, CCR4 is linked to neoplasm.